Lv4
408 积分 2022-09-16 加入
Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, in Chinese people with type 2 diabetes mellitus
3天前
已完结
Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
3天前
已完结
Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double‐blind, placebo‐controlled, phase 3 trial
3天前
已完结
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
3天前
已完结
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone
3天前
已完结
Ertugliflozin in type 2 diabetes: a profile of its use
3天前
已完结
Empagliflozin: A Review in Type 2 Diabetes
3天前
已完结
Canagliflozin: A Review in Type 2 Diabetes
3天前
已完结
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
3天前
已完结
An evaluation of canagliflozin for the treatment of type 2 diabetes: an update
3天前
已完结
皖公网安备34019202002308
